Egrifta Approval: FDA Balanced Modest Efficacy, Off-Label Use Potential With Unmet Medical Need

The approval of Theratechnologies’ HIV lipodystrophy treatment Egrifta (tesamorelin) shows how much FDA can be swayed by unmet need, even where the product has limited efficacy in a narrow population and substantial potential for off-label use.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet